- Previous Close
0.2780 - Open
0.2740 - Bid 0.2700 x --
- Ask 0.3520 x --
- Day's Range
0.2740 - 0.2740 - 52 Week Range
0.2520 - 1.5700 - Volume
50,939 - Avg. Volume
837 - Market Cap (intraday)
303.888M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company's product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody that prevents the immune escape of tumor cells; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
www.alphamabonc.comRecent News: 3NK.F
Performance Overview: 3NK.F
Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3NK.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3NK.F
Valuation Measures
Market Cap
308.32M
Enterprise Value
157.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.31
Price/Book (mrq)
1.22
Enterprise Value/Revenue
5.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-96.26%
Return on Assets (ttm)
-9.50%
Return on Equity (ttm)
-13.04%
Revenue (ttm)
218.77M
Net Income Avi to Common (ttm)
-210.59M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.41B
Total Debt/Equity (mrq)
15.38%
Levered Free Cash Flow (ttm)
-179.06M